MINNEAPOLIS, Minn., June 28, 2018 – Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cellular therapies, today announced the appointment of Mark Flower as Vice President, Business Development and Strategic Partnerships, and Erin Rasch as Senior Director, Sales and New Business Development.

“We are delighted to expand our business development team with these important new hires,” said Amy Ronneberg, President of Be The Match BioTherapies. “We look forward to leveraging Mark and Erin’s collective insights into the challenges facing developers of commercial cell therapies to build additional industry partnerships, with the ultimate goal of helping to deliver innovative, life-altering treatments to patients with cancer and other diseases.”

Flower brings more than 12 years of experience working in the field of immuno-oncology, cell based gene and immunotherapy, cell therapy manufacturing and bioprocessing. Previously, he served as the Executive Director of Sales and Marketing at Hitachi Chemical Advanced Therapeutics Solutions, and as Senior Manager, Global Strategic Marketing, in the Therapeutic Systems business unit at Terumo BCT. In those roles he lead the sales and marketing team, and  successfully launched  multiple devices and technologies in the field of stem cell collection via leukapheresis, cell isolation, cell processing and culture. His relationships extend from commercial cell therapy developers to leading academic and research centers that serve as the clinical trial sites for numerous innovative cell therapies. Flower is a member of the International Society for Cellular Therapy (ISCT) and the Society for Immunotherapy of Cancer (SITC). He graduated from the University of California, San Diego with a B.S. in Biological Sciences.

Rasch joins Be The Match BioTherapies with more than 10 years of biotechnology development services experience. Previously, she served as Vice President of Sales and Marketing at Cell Culture Company (C3), a Minneapolis-based contract manufacturing organization focused on providing cell culture services to clinical-stage pharmaceutical and diagnostic organizations. She was successful in rapidly growing the pipeline of that organization and establishing C3 as one of the go-to organizations for small-scale GMP manufacturing in the U.S. Prior to C3, she worked at DCI-Biolafitte in Minnesota as a Sales Engineer specializing in bioreactors and other process equipment. She began her biomanufacturing career at Verenium Corporation in San Diego as a manufacturing process engineer. She holds an M.S. in Bioengineering from the University of California, San Diego, and graduated summa cum laude with a B.S. in Chemical Engineering from Auburn University. She is involved in multiple life science industry organizations.

About Be The Match BioTherapies
Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development and is leading efforts to standardize the cell therapy supply chain to ease the burden on the existing infrastructure. Built on the foundation established over the last 30 years by the National Marrow Donor Program®/Be The Match®, the organization has unparalleled experience managing cellular therapies. Its cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and MatchSource®, a software platform. By leveraging its deep experience in cell sourcing and collection, Be The Match BioTherapies provides cells consented for research, clinical or commercial use as well as clinical trials services through its research program, the CIBMTR. In addition, Be The Match BioTherapies has the infrastructure in place to collect patient outcomes at the time points required by regulatory authorities. For more information, please visit BeTheMatchBioTherapies.com.

Media Contact

Be The Match BioTherapies:
Lisa Raffensperger
Ten Bridge Communications
(617) 903-8783